US Markets Closed

AI-assisted · Not financial adviceNot advice

AI-assisted · Not financial advice.

US Markets Closed

AI-assisted · Not financial adviceNot advice

US Markets Closed

AI-assisted · Not financial adviceNot advice

$HIMS

Name: HIMS (Hims & Hers Health) — Market Sentiment & Discussion
Creator: MarketMind
License: https://stockmarketsentimentai.com/methodology

Hims & Hers Health· 4/5/2026, 6:04:47 PM

Data Checks· 1 of 3 passed

Analyst target

1% downside · 11 analysts · $13–$60 range

▼ $30

Earnings

EPS: $0.41 → $0.58 (2026 vs 2027)

▲ Expected to grow 41%

Insiders (90d)

0 buys, 8 sells

Last: SELL Mar 20· 16d ago

▼Net selling $3.7M

Reddit: MixedAttention: Watching

Community Take (7D)

Retail skepticism about product safety and competition aligns with news of growth challenges. This suggests a cautious approach to HIMS investments, weighing potential risks against growth opportunities.

News vs Reddit

Wait & See

News: divided · 65% qualityReddit: neutral · 0% confidence

The Story

News Summary

Hims & Hers faces growth challenges

Key Events

Mar 1, 2001:Hims & Hers shares show promise despite initial guidance challenges.
Feb 27, 2001:Hims expands into labs, cancer screening, and menopause.
Feb 26, 2001:Hims stock beat on earnings but suffered a steep sales slowdown in Q4.

Sentiment: 60% bullish / 40% neutral (early) → 50% bearish / 30% cautious / 20% bullish (late)

Impact: The early narrative focused on expansion and growth potential, while later discussions highlighted significant sales challenges and cautious outlooks.

Risks: regulatory uncertainty, margin erosion

Analyst ConsensusHold (19 analysts)

Target: $30 avg (-1% upside)

6 Buy · 13 Hold · 0 Sell

Signal

Divided

Confidence

65%

Based on curated news sources (not retail comments)

Over the last 7 days: Despite strong revenue growth and positive guidance, regulatory scrutiny and margin pressures create a conflicting outlook for Hims & Hers.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B [FMP|Feb 24]
✓Management guided FY26 revenue of $2.7–$2.9B, signaling continued investment in international expansion [FMP|Feb 24]
✓Hims & Hers Health reported fourth-quarter revenue of $617.82 million, beating earnings estimates [FMP|Feb 23]

Risk Factors

✗Hims & Hers disclosed an SEC investigation into its compounded semaglutide disclosures, creating uncertainty [FMP|Feb 24]
✗The company faces near-term margin pressure and a softer outlook due to GLP-1 headwinds [FMP|Feb 24]
✗Hims stock has been under pressure this year, with a steep sales slowdown reported [FMP|Feb 26]

Analyze with AI yahoo!finance Reddit Answers

AI-assisted · Not financial advice.

$HIMS - Hims & Hers Health | MarketMind | MarketMind

$HIMS

Hims & Hers Health· 4/5/2026, 6:04:47 PM

Data Checks· 1 of 3 passed

Analyst target

1% downside · 11 analysts · $13–$60 range

▼ $30

Earnings

EPS: $0.41 → $0.58 (2026 vs 2027)

▲ Expected to grow 41%

Insiders (90d)

0 buys, 8 sells

Last: SELL Mar 20· 16d ago

▼Net selling $3.7M

Options positioning: Bullish — More betting on upside (2.4× more call than put volume today). Unusual bets on $20 upside — 11× normal activity. analysts: 6 buy vs 0 sell.

Reddit: MixedAttention: Watching

Community Take (7D)

News vs Reddit

Wait & See

News: divided · 65% qualityReddit: neutral · 0% confidence

The Story

News Summary

Hims & Hers faces growth challenges

Key Events

Mar 1, 2001:Hims & Hers shares show promise despite initial guidance challenges.
Feb 27, 2001:Hims expands into labs, cancer screening, and menopause.
Feb 26, 2001:Hims stock beat on earnings but suffered a steep sales slowdown in Q4.

Sentiment: 60% bullish / 40% neutral (early) → 50% bearish / 30% cautious / 20% bullish (late)

Impact: The early narrative focused on expansion and growth potential, while later discussions highlighted significant sales challenges and cautious outlooks.

Risks: regulatory uncertainty, margin erosion

Analyst ConsensusHold (19 analysts)

Target: $30 avg (-1% upside)

6 Buy · 13 Hold · 0 Sell

Signal

Divided

Confidence

65%

Based on curated news sources (not retail comments)

Over the last 7 days: Despite strong revenue growth and positive guidance, regulatory scrutiny and margin pressures create a conflicting outlook for Hims & Hers.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B [FMP|Feb 24]
✓Management guided FY26 revenue of $2.7–$2.9B, signaling continued investment in international expansion [FMP|Feb 24]
✓Hims & Hers Health reported fourth-quarter revenue of $617.82 million, beating earnings estimates [FMP|Feb 23]

Risk Factors

✗Hims & Hers disclosed an SEC investigation into its compounded semaglutide disclosures, creating uncertainty [FMP|Feb 24]
✗The company faces near-term margin pressure and a softer outlook due to GLP-1 headwinds [FMP|Feb 24]
✗Hims stock has been under pressure this year, with a steep sales slowdown reported [FMP|Feb 26]

Analyze with AI yahoo!finance Reddit Answers